The Personalization of Major Depressive Disorder treatment using heterogeneity of depression
DOI:
https://doi.org/10.58445/rars.991Keywords:
Major Depressive Disorder, Treatment, Biomarkers, Risk FactorsAbstract
There have been trends of increased prevalence of depression disorders worldwide, namely after the COVID-19 pandemic. Major Depressive Disorder (MDD) is the one of the most common mental health conditions in the world, as it affects 3.8% of the global population; however, the condition often generalizes the complex manifestation of symptoms of the disorder, which creates a broad definition and diagnosis of MDD. There are various causes and symptoms that are influenced by genetics, the environment, and development. It is important to create more precise diagnosis in order to better treat depression patients and accommodate their specific needs. SSRI antidepressants are commonly the first prescribed treatment for depression, but they often do not encompass the heterogeneity of depression. By analyzing combinations of biomarkers, risk factors, and treatments of depression, potential directions can be approached to identify paths to make treatment more personalized.
References
Akil, H., Gordon, J., Hen, R., Javitch, J., Mayberg, H., McEwen, B., Meaney, M. J., & Nestler, E. J. (2018). Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience and biobehavioral reviews, 84, 272–288. https://doi.org/10.1016/j.neubiorev.2017.08.019
Al-Harbi, K. S. (2012). Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient preference and adherence, 6, 369–388. https://doi.org/10.2147/PPA.S29716
Basbaum, A. I., & Fields, H. L. (1978). Endogenous pain control mechanisms: review and hypothesis [Abstract]. Annals of neurology, 4(5), 451–462. https://doi.org/10.1002/ana.410040511
Chu, A., & Wadhwa, R. (2023). Selective serotonin reuptake inhibitors. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK554406/
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020). Prevalence of depression symptoms in US adults before and during the COVID-19 Pandemic. JAMA network open, 3(9), e2019686.
Goodwin, G. M. (2006). Depression and associated physical diseases and symptoms. Dialogues in clinical neuroscience, 8(2), 259–265. https://doi.org/10.31887/DCNS.2006.8.2/mgoodwin
Hillhouse, T. M., & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and clinical psychopharmacology, 23(1), 1–21. https://doi.org/10.1037/a0038550
Höller, Y., Urbschat, M. M., Kristófersson, G. K., & Ólafsson, R. P. (2022). Predictability of seasonal mood fluctuations based on self-report questionnaires and EEG biomarkers in a non-clinical sample. Frontiers in psychiatry, 13, 870079. https://doi.org/10.3389/fpsyt.2022.870079
Klein, D. N., Kotov, R., & Bufferd, S. J. (2011). Personality and depression: explanatory models and review of the evidence. Annual review of clinical psychology, 7, 269–295. https://doi.org/10.1146/annurev-clinpsy-032210-104540
Lester, D. (2021). Depression, Suicidal Ideation and the Big Five Personality Traits. Austin J Psychiatry Behav Sci, 7(1), 1077. https://austinpublishinggroup.com/psychiatry-behavioral-sciences/fulltext/ajpbs-v7-id1077.php
Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017). The role of neural plasticity in depression: From hippocampus to prefrontal cortex. Neural plasticity, 2017, 6871089. https://doi.org/10.1155/2017/6871089
Lohoff, F. W. (2010). Overview of the genetics in major depressive disorder. Current psychiatry reports, 12(6), 539–546. https://doi.org/10.1007/s11920-010-0150-6
Nabeshima, T., & Kim, H. (2013). Involvement of genetic and environmental factors in the onset of depression. Experimental neurobiology, 22(4), 235–243. https://doi.org/10.5607/en.2013.22.4.235
Norkeviciene, A., Gocentiene, R., Sestokaite, A., Sabaliauskaite, R., Dabkeviciene, D., Jarmalaite, S., & Bulotiene, G. (2022). A systematic review of candidate genes for major depression. Medicina (Kaunas, Lithuania), 58(2), 285. https://doi.org/10.3390/medicina58020285
Ohrnberger, J., Fichera, E., & Sutton, M. (2017). The relationship between physical and mental health: A mediation analysis. Social Science & Medicine, 195, 42–49. https://doi.org/10.1016/j.socscimed.2017.11.008
Rădulescu, I., Drăgoi, A. M., Trifu, S. C., & Cristea, M. B. (2021). Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review). Experimental and therapeutic medicine, 22(4), 1131. https://doi.org/10.3892/etm.2021.10565
Shadrina, M., Bondarenko, E. A., & Slominsky, P. A. (2018). Genetic factors in major depression disease. Frontiers in psychiatry, 9, 334. https://doi.org/10.3389/fpsyt.2018.00334
Stein, K., Maruf, A. A., Müller, D. J., Bishop, J. R., & Bousman, C. A. (2021). Serotonin transporter genetic variation and antidepressant response and tolerability: A systematic review and meta-analysis. Journal of personalized medicine, 11(12), 1334. https://doi.org/10.3390/jpm11121334
Stegenga, B. T., Nazareth, I., Grobbee, D. E., Torres-González, F., Svab, I., Maaroos, H. I., Xavier, M., Saldivia, S., Bottomley, C., King, M., & Geerlings, M. I. (2012). Recent life events pose greatest risk for onset of major depressive disorder during mid-life. Journal of affective disorders, 136(3), 505–513. https://doi.org/10.1016/j.jad.2011.10.041
Trivedi, M. H. (2004). The link between depression and physical symptoms. Primary care companion to the Journal of clinical psychiatry, 6(Suppl 1), 12–16.
World Health Organization. (2022). COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide
World Health Organization. (2023). Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression
Zhang, F. F., Peng, W., Sweeney, J. A., Jia, Z. Y., & Gong, Q. Y. (2018). Brain structure alterations in depression: Psychoradiological evidence. CNS neuroscience & therapeutics, 24(11), 994–1003. https://doi.org/10.1111/cns.12835
Downloads
Posted
Categories
License
Copyright (c) 2024 Grace Peng
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.